Perspective Therapeutics (NYSE:CATX) Earns “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a report issued on Thursday,RTT News reports. They currently have a $11.00 price objective on the stock, down from their previous price objective of $20.00.

Several other analysts also recently issued reports on CATX. Truist Financial initiated coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective for the company. Oppenheimer reiterated an “outperform” rating and set a $22.00 price target on shares of Perspective Therapeutics in a report on Friday, October 11th. Bank of America assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective on the stock. Royal Bank of Canada cut their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $19.43.

Perspective Therapeutics Stock Up 15.7 %

NYSE CATX opened at $3.47 on Thursday. The company has a 50 day simple moving average of $11.52. Perspective Therapeutics has a 12-month low of $2.28 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million during the quarter. As a group, analysts anticipate that Perspective Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

Several institutional investors have recently made changes to their positions in CATX. nVerses Capital LLC bought a new position in Perspective Therapeutics during the third quarter worth about $57,000. US Bancorp DE lifted its position in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after buying an additional 3,866 shares during the period. Victory Capital Management Inc. bought a new stake in Perspective Therapeutics in the second quarter valued at $117,000. Point72 DIFC Ltd bought a new stake in Perspective Therapeutics in the second quarter valued at $118,000. Finally, Intech Investment Management LLC acquired a new position in Perspective Therapeutics during the third quarter worth $137,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.